NASDAQ: LNSRLensar Inc Stock
$6.13-0.06 (-0.97%)
Updated Jul 7, 2026
LNSR Price
$6.13
Fair Value Price
N/A
Market Cap
$74.20M
52 Week Low
$5.06
52 Week High
$13.43
P/E
6.26x
P/B
6.88x
P/S
1.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.70M
Earnings
$29.39M
Gross Margin
45.7%
Operating Margin
50.94%
Profit Margin
50.9%
Debt to Equity
3.86
Operating Cash Flow
-$12M
Beta
0.46
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LNSR Overview
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LNSR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LNSR
Ranked#87 of 94
Ranked#87 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.49 | A | |
| $45.70 | A | |
| $31.49 | A |
Be the first to know about important LNSR news, forecast changes, insider trades & much more!
LNSR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LNSR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LNSR is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LNSR is good value based on its earnings relative to its share price (6.26x), compared to the US market average (8.58x)
P/E vs Market Valuation
LNSR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more LNSR due diligence checks available for Premium users.
Valuation
LNSR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
6.26x
Industry
21.42x
Market
8.58x
LNSR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LNSR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
LNSR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.88x
Industry
3.12x
LNSR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LNSR's financial health
Profit margin
Revenue
$13.4M
Net Income
$36.3M
Profit Margin
270.5%
LNSR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LNSR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.2M
Liabilities
$41.6M
Debt to equity
3.86
LNSR's short-term assets ($42.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LNSR's short-term assets ($42.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LNSR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LNSR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$4.0M
Financing
-$209.0k
LNSR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LNSR vs Medical Device Stocks
Lensar Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.